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vaginal cytology without reference to general health and development. If this was so, a logical question to be answered was why not include in the 'premature menopause group' every female infant whose vagina ceased to be influenced by the maternal aestrogen which nourished it in utero ?
Conflicting evidence had been presented concerning the incidence of hypertension associated with the administration of oral contraceptives and nothing had been said about changes in the clotting factors during cestrogen therapy. He hoped that Dr Zussman and his team proposed to investigate these important issues in the prospective scientific study which they planned. If they confirmed the work of others indicating that changes might occur which could be serious this would provide arguments against routine postmenopausal cestrogen therapy. Dr Zussman had correctly said that there were many therapeutic measures now available for helping menopausal and postmenopausal women. However, Sir John concluded that there was, in his opinion, no scientific evidence to support the universal administration of hormones.
Professor Peter Curzen (Westminster Medical School, London SWI) said that Dr Zussman's paper had been both stimulating and provocative. There was general acceptance of the view that women with menopausal symptoms should be treated. Furthermore, the short-term systemic administration of aestrogens constituted an important facet of such treatment. However, Dr Zussman seemed to advocate long-term prophylactic administration of cestrogens for the remainder of the postmenopausal woman's life. His principal argument in support of this view was that prophylactic cestrogens should reduce the incidence and severity of those degenerative processes which often become accelerated after the menopause, and which interfere with the psychological, somatic and sexual wellbeing of the postmenopausal patient.
There was certainly considerable biochemical, radiological and epidemiological evidence to show that the incidence of osteoporosis increases after the menopause. There was also some evi-dence that the biochemical disturbances characteristic of osteoporosis could be prevented, but not reversed, by oestrogen therapy. However, the incidence of symptomatic as distinct from asymptomatic osteoporosis had not been clearly established, and it was difficult to assess how much of a clinical problem this constituted.
There was also considerable evidence to support the view that the much lower incidence of major cardiovascular disease in premenstrual women as compared with men might be due to aestrogens. After the menopause this difference in incidence greatly lessened, until the eighth decade of life, when the incidence was approximately the same in both sexes. Plasma levels of cholesterol, phospholipids and triglycerides tended to rise after the menopause. High levels of these substances were often associated with major cardiovascular disease and had been incriminated as a causative factor in such diseases by some workers. The administration of systemic estrogens tended to reduce plasma levels of these substances in postmenopausal women. However, there was no evidence to show that systemic cestrogens reduced the incidence of major cardiovascular disease after the menopause. Even if they did, the possible domestic and social consequences of artificially maintaining the sex differential for major cardiovascular disease in the later decades of life would require careful consideration.
Dr Zussman considered that the postmenopausal administration of cestrogens was important to maintain the libido as well as the frequency and quality ofcoitus. However, it had been shown that in many postmenopausal women not receiving cestrogens, sexual function improved spontaneously as a result of freedom from the fear of a possible pregnancy. Furthermore, sexual function after the menopause appeared to be closely related to its function before.
Dr Zussman's enthusiasm for the long-term prophylactic use ofcestrogens after the menopause was obviously based on a very strong sense of personal conviction which was shared by his co-workers. However, in Professor Curzen's opinion, statistical proof was lacking and could only be provided by a properly controlled trial. Even if such a trial substantiated the usefulness of this form of treatment, its possible widespread implementation within our National Health Service would have to be considered carefully in relation to other priorities.
